Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.69 |
| ▸ | DRD3 | P35462 | 13/20 | 0.69 |
| ▸ | DRD4 | P21917 | 3/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646496 | 1.00 | DRD2 (0.69) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL19358713 | 0.87 | DRD2 (0.55) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL19358714 | 0.87 | DRD2 (0.55) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL1907578 | 0.84 | DRD2 (0.86) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL1080392 | 0.81 | DRD2 (0.95) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL4917290 | 0.81 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL10153112 | 0.81 | DRD2 (0.66) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL16403430 | 0.81 | DRD2 (0.66) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL2214157 | 0.80 | DRD2 (0.67) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL644477 | 0.79 | DRD2 (0.59) | DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119642-B2 | Structurally rigid dopamine D3 receptor selective ligands and process for making them | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100068138-A1 | STRUCTURALLY RIGID DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND PROCESS FOR MAKING THEM | NEWMAN AMY | 2010-03-18 | — | — | US | disclosed |
| US-7605259-B2 | N-(4-(4-(2,3 -dichlorophenyl)piperazin-1-yl)but-2-enyl)-1H-indole-2-carboxamide; imaging agents; tomography;diagnosis/medical/; selective, oral bioavailable drugs; nervous system disorders; central nervous system;oral administration; substance abuse ( cocaine/amphetamine); psychosis; Parkinson's | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH (US) | 2009-10-20 | — | — | US | disclosed |
| US-20060106030-A1 | Structurally rigid dopamine d3 receptor selective ligands and process for making them | GOV'T OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106030-A1 | Structurally rigid dopamine d3 receptor selective ligands and process for making them | DRD3, OPRD1, DRD2 | DRD2 3/4885DRD3 1/4885DRD4 8/4885 |
| US-20100068138-A1 | STRUCTURALLY RIGID DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND PROCESS FOR MAKING THEM | DRD3, OPRD1, DRD2 | DRD2 3/4885DRD3 1/4885DRD4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.